Feb 28, 2015 by Brian Orelli, PhDWhoa, a Profit for Isis Pharmaceuticals Inc.Don't get too excited just yet.
Feb 26, 2015 by Brian Orelli, PhDOrexigen Therapeutics, Inc. Gives the Skinny on Its Drug LaunchFourth-quarter earnings were nothing to get excited about, but the Contrave launch trajectory looks good so far.
Feb 25, 2015 by Brian Orelli, PhD"Profitability" in Sight for BioMarin Pharmaceutical Inc.2017 could be the year for the orphan-drug maker.
Feb 25, 2015 by Brian Orelli, PhDMannKind Corporation in TransitionA drug on the market for two weeks makes for a boring earnings call.
Feb 25, 2015 by Brian Orelli, PhDLooking Ahead at Exelixis, Inc.The biotech faces two major value-creating events in 2015.
Feb 25, 2015 by Brian Orelli, PhD5 Things Biogen Idec Inc's Management Wants You to KnowPipeline data, new drug launches, and sales of established drugs top the list.
Feb 24, 2015 by Brian Orelli, PhDMeet MannKind Corporation's New Boss (No, the Other One)Sanofi's new CEO Olivier Brandicourt will have an impact on the success of MannKind's Afrezza.
Feb 17, 2015 by Brian Orelli, PhDWaiting for the Momenta to RegainMomenta Pharmaceuticals waits on potential partner(s), the FDA, and the court system.
Feb 12, 2015 by Brian Orelli, PhDLoaded-Up Alnylam Pharmaceuticals, Inc. Progresses Its PipelineWith plenty of cash on hand, Alnylam Pharmaceuticals' fourth-quarter "earnings" call was all about the pipeline.
Feb 11, 2015 by Brian Orelli, PhDGenomic Health, Inc. on the Road to ProfitabilityA few more quarters of losses to bear first, though.
Feb 10, 2015 by Brian Orelli, PhDSeattle Genetics, Inc. Exceeds ExpecationsYou can't ask for more than beating raised guidance, except for profitability, of course.
Feb 10, 2015 by Brian Orelli, PhDDon't Worry About Orexigen's Obesity Drug EU ApprovalDespite what looks initially like bad news for the oral obesity drug, a positive European Commission decision is still likely.
Feb 7, 2015 by Brian Orelli, PhDWhat's Bad For Gilead Sciences and Merck Is a Good Sign for PatientsFrom Breakthrough to me, too.
Feb 6, 2015 by Brian Orelli, PhDInhaled Insulin Now Available in the U.S. (Again)MannKind and Sanofi launch Afrezza. Can it perform better than Exubera?
Feb 3, 2015 by Brian Orelli, PhDGilead Sciences, Inc. Earnings: We'll Make Up for It in VolumeDiscounts on Gilead's hepatitis C drugs will increase substantially, but so will the number of treated patients.
Jan 30, 2015 by Brian Orelli, PhDHold Your Horses, IDEXX Laboratories, Inc. Earnings Are Better Than They AppearA switch to a direct-to-customer sales model creates one-time costs.
Jan 30, 2015 by Brian Orelli, PhDImmunoGen, Inc. Gets Into the Black, Accounting WiseBut it's still burning cash.
Jan 29, 2015 by Brian Orelli, PhDBiogen Idec Inc Earnings: Worth the WaitSnow storms can't slow Biogen Idec's sales growth.
Jan 29, 2015 by Brian Orelli, PhDCelgene Corp.'s Expanding MarginsBut it wasn't all the healthy kind of expansion.
Jan 28, 2015 by Brian Orelli, PhDNo Surprises From Vertex Pharmaceuticals Incorporated. Yet.Having pre-released revenue and guidance at J.P. Morgan, Vertex didn't offer much news on its earnings call, although we should get news soon.
